2025-04-01 - Analysis Report
## Teva Pharmaceutical Industries Ltd ADR (TEVA) Stock Report

**0. Key Figures:**

* **Current Price:** $15.49
* **Cumulative Return (TEVA):** 23.92%
* **Cumulative Return (VOO/S&P 500):** 91.19%
* **Return Difference (TEVA vs VOO):** -67.3%
* **Relative Divergence:** 45.9% (Indicates TEVA's performance is relatively lower than VOO, but not at its lowest historical point compared to VOO.)


**1. Company Overview and Performance Comparison:**

Teva Pharmaceutical Industries Ltd ADR is a global pharmaceutical company specializing in generic and specialty medicines.  Its cumulative return significantly underperforms the S&P 500 (VOO) over the analyzed period, with a difference of -67.3%.  This signifies substantial underperformance relative to the broader market.  The relative divergence suggests this underperformance is significant but not historically unprecedented.

**Alpha and Beta Analysis:**

The provided data shows consistently negative alpha values across all periods, indicating TEVA underperforms the market benchmark (likely the S&P 500)  by a considerable margin.  The high beta values (especially in the earlier periods) suggest high volatility and sensitivity to market movements.  However, the beta has decreased significantly in the recent periods (2022-2024 and 2023-2025).

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | -42.0% | 50.4% | -59.0% | -0.1 | 22.4 |
| 2016-2018  | -47.0% | 50.4% | -53.0% | -0.1 | 18.2 |
| 2017-2019  | -19.0% | 50.4% | -39.0% | -0.1 | 11.6 |
| 2018-2020  | -5.0% | 48.3% | -39.0% | -0.1 | 11.4 |
| 2019-2021  | -19.0% | 41.2% | -92.0% | -0.1 | 9.4 |
| 2020-2022  | 9.0% | 57.9% | -2.0% | -0.1 | 10.8 |
| 2021-2023  | 11.0% | 57.9% | -7.0% | -0.4 | 12.3 |
| 2022-2024  | 96.0% | 57.9% | 74.0% | -0.3 | 26.0 |
| 2023-2025  | 57.0% | 75.6% | 15.0% | -0.1 | 18.3 |


**2. Recent Price Movement:**

* **Closing Price:** $15.49
* **5-Day Moving Average:** $15.83
* **20-Day Moving Average:** $15.98
* **60-Day Moving Average:** $18.09

The price is below all three moving averages, suggesting a downtrend.  The recent price increase (Last-market data shows a 2.79% increase) might be a temporary bounce.


**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4283 (Medium Risk)
* **RSI:** 51.47 (Slightly above neutral; neither overbought nor oversold)
* **PPO:** 0.19 (Positive, suggesting potential upward momentum)
* **20-Day Relative Divergence Change:** -4.3% (Short-term downward trend)
* **Expected Return (vs S&P 500, long-term):** -101.1% (This suggests significant underperformance relative to the S&P 500 over a long-term horizon.  This number requires further investigation into its calculation methodology).  The 2.79% price increase needs to be considered in the context of this significant negative long-term expected return.


**4. Recent Earnings Analysis:**

| 날짜       | EPS       | 매출       |
|------------|-----------|-----------|
| 2024-11-06 | -$0.39     | $4.33B     |
| 2024-07-31 | -$0.75     | $4.16B     |
| 2024-05-08 | -$0.12     | $3.82B     |
| 2023-11-09 | $0.07      | $3.85B     |
| 2024-02-12 | $0.06      | $3.85B     |

The recent earnings show inconsistent profitability, with several quarters reporting negative EPS. Revenue has been relatively stable, but the negative EPS raises serious concerns about the company's financial health.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $4.23B | 50.15% |
| 2024-09-30 | $4.33B | 49.60% |
| 2024-06-30 | $4.16B | 48.61% |
| 2024-03-31 | $3.82B | 46.37% |
| 2023-12-31 | $4.46B | 54.18% |

Profit margins are relatively high but show a slight downward trend. Revenue is relatively consistent but not showing significant growth.

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $5.37B | -4.04% |
| 2024-09-30 | $6.07B | -7.21% |
| 2024-06-30 | $6.36B | -13.30% |
| 2024-03-31 | $7.28B | -1.91% |
| 2023-12-31 | $7.51B | 5.72% |

Negative ROE in recent quarters is a major concern, indicating the company is not generating sufficient returns on its equity.


**6. Overall Analysis:**

TEVA shows significant underperformance compared to the S&P 500, with negative alpha and high volatility (beta).  Recent earnings reveal inconsistent profitability and negative ROE, raising serious concerns about the company's financial health. While the recent price increase provides a short-term positive signal, the long-term outlook appears negative based on the provided data. Technical indicators show mixed signals, with the price trading below its moving averages but RSI and PPO suggesting some potential upward momentum. The extremely negative long-term expected return (-101.1%) strongly suggests caution is warranted.  Further investigation is needed into the calculation methodology of this long-term expected return, and a thorough due diligence process is highly recommended before any investment decision.  The negative expected return in conjunction with weak financials casts significant doubt on the viability of a long-term investment strategy in TEVA.
